CotinineCotinine
MedChemExpress (MCE)
HY-B1178
486-56-6
(-)-Cotinine
(S)-Cotinine
NIH-10498
98.46%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Cotinine ((-)-Cotinine) is an orally active alkaloid found in tobacco and is the primary metabolite of nicotine. Cotinine is metabolized by CYP2A13 into trans-3'-hydroxycotinine. Cotinine is used as a biomarker to measure exposure to tobacco smoke components. Cotinine has vasodepressor activity. The mixture of cotinine and nicotine (Nicotine) has antiproliferative activity against pterygium. (S)-(-)-Cotinine activates nicotinic acetylcholine receptors (nAChR) in a calcium-dependent manner, leading to the release of dopamine (Dopamine, HY-B0451). Cotinine ((-)-Cotinine) is used in research related to cardiovascular and inflammatory diseases.
Mixture of Cotinine and Nicotine (2 μM Cotinine + 0.15 μM Nicotine, 7 days) retards the proliferation rate of human primary pterygium cells[4]. (S)-(-)-Cotinine (1–100 μM) was inhibited by the nicotinic receptor antagonists Mecamylamine (HY-B1395A) and Dihydro-β-erythroidine (HY-N10497) in the inhibition of dopamine release from rat striatal slices[5]. (S)-(-)-Cotinine (10–1000 μM) was inhibited in the release of dopamine from rat striatal slices by treatment with a low calcium buffer[5].
Cotinine (1 mg/kg (Nicotine), i.v., sampled at 5-60 min after administration) has a long biological half-life (19-24 hours) in Sprague-Dawley rats and is retained and accumulated in plasma for an extended period[2].
| | | |
| | | | | |
[1]. Dolcini MM, et al. An assessment of the validity of adolescent self-reported smoking using three biological indicators. Nicotine Tob Res. 2003 Aug
5(4):473-83. [Content Brief]
[2]. Sastry BV, et al. Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. Pharmacology. 1995 Feb
50(2):128-36. [Content Brief]
[3]. Borzelleca J F, et al. Studies on the respiratory and cardiovascular effects of (-)-cotinine[J]. Journal of Pharmacology and Experimental Therapeutics, 1962, 137(3): 313-318. [Content Brief]
[4]. Yang Q, et al. Continuous exposure of nicotine and cotinine retards human primary pterygium cell proliferation and migration. [Content Brief]
[5]. Dwoskin L P, et al. (S)-(−)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H] dopamine release from rat striatal slices in a calcium-dependent manner[J]. Journal of pharmacology and experimental therapeutics, 1999, 288(3): 905-911. [Content Brief]